Multicenter phase I dose escalation and expansion study of pyrotinib in combination with camrelizumab and chemotherapy as first-line treatment for HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma

BACKGROUND: Pembrolizumab plus trastuzumab and chemotherapy showed remarkable efficacy as first-line therapy for advanced HER2-positive gastric cancer. Pyrotinib is an irreversible pan-HER inhibitor. This single-arm, open-label phase 1 dose-escalation (1a) and expansion (1b) study investigated camre...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Sheng, Bao, Jun, Li, Xiaoyou, Yang, Quanliang, Xu, Junying, Chen, Surong, Feng, Ge, Gao, Chao, Feng, Lin, Lu, Bin, Miao, Min, Ni, Xinchu, Wang, Guofang, Yang, Lei, Zhu, Liangjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679498/
https://www.ncbi.nlm.nih.gov/pubmed/38024480
http://dx.doi.org/10.1016/j.eclinm.2023.102314

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679498/
https://www.ncbi.nlm.nih.gov/pubmed/38024480
http://dx.doi.org/10.1016/j.eclinm.2023.102314

Ejemplares similares